Inversago Pharma

Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based cardiometabolic disorder specialist Inversago Pharma by the end of the year, subject to regulatory approvals and other customary conditions. The acquisition deal could reach a total value of USD 1.1 billion if all development and…